Healthy Volunteers, Pharmacokinetics of Mirabegron
Conditions
Keywords
Pharmacokinetics, Oral contraceptives, Drug interactions, Pharmacokinetics of mirabegron
Brief summary
The objective of this study is to determine the effect of multiple doses of mirabegron on the pharmacokinetics of an oral contraceptive.
Interventions
DRUGMirabegron
Oral
DRUGMinidril
Oral
DRUGPlacebo
Oral
Sponsors
Astellas Pharma Inc
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects above 35 years inclusive are re-evaluated for the risks of using of a COC * Body Mass Index between 18.5 and 30.0 kg/m2, inclusive * On oral contraceptive with 30ʯg ethinyl estradiol (EE) plus either 125ʯg or 150ʯg levonorgestrel (LNG) for at least three months prior to date of randomization and well tolerated * During the study the subject is willing to use 1 of the 3 following contraceptive methods: diaphragm with spermicide, intrauterine device or partner is using condoms in combination with a spermicidal cream
Exclusion criteria
Subjects will be excluded from participation if any of the following apply: * Known or suspected hypersensitivity to YM178 or any components of the formulation used * Pregnant or breast feeding within 6 months before screening assessment * Any of the liver function tests (i.e. ALT, AST and Alkaline phosphatase) above the upper limit of normal * Any clinically significant history of asthma, eczema, any other allergic condition or previous severe hypersensitivity to any drug (excluding non-active Hay-fever) * Any clinically significant history of any other disease or disorder - gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological, dermatological, psychiatric or metabolic as judged by the medical investigator * Any clinically significant abnormality following the investigator's review of the pre-study physical examination, ECG and clinical laboratory tests * Abnormal pulse and/or blood pressure measurements at the pre-study visit as follows: Pulse \<40 or \>90 bpm; mean systolic blood pressure \>140 mmHg; mean diastolic blood pressure \>90 mmHg (blood pressure measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse will be measured automatically) * A marked baseline prolongation of QT/QTc interval after repeated measurements of \>450 ms, a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS) * Use of any prescribed or OTC (over-the-counter) drugs (including vitamins, natural and herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the Clinical Unit, except for occasional use of paracetamol (up to 3 g/day) * Regular use of any inducer of liver metabolism (e.g. barbiturates, rifampin) in the 3 months prior to admission to the Clinical Unit * Any use of drugs of abuse within 3 months prior to admission to the Clinical Unit * History of drinking more than 14 units of alcohol per week (1 unit = 270 cc of beer or 40 cc of spirits or 1 glass of wine) within 3 months prior to admission to the Clinical Unit * Positive test for drugs of abuse or positive alcohol test on the day of admission into the clinical unit * History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the Clinical Unit * Participation in any clinical study within 3 months or participation in more than 3 clinical studies within 12 months, prior to the expected date of enrolment into the study * Donation of blood or blood products within 3 months prior to admission to the Clinical Unit * Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2 * Subjects who, in the opinion of the investigator, are not likely to complete the trial for any reason * Unwillingness to use additional barrier contraceptive methods for the course of the study and for one month after the end of study visit * Any clinical condition, which, in the opinion of the investigator would not allow safe completion of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of pharmacokinetics of Ethinyl estradiol (EE) and Levonorgestrel (LNG) by analysis of blood samples. | Day 21 + Day 29 |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of pharmacokinetics of mirabegron by analysis of blood samples. | Day 21 + Day 49 |
Countries
France
Outcome results
None listed